WallStreetZenWallStreetZen

NASDAQ: REVB
Revelation Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their REVB stock forecasts and price targets.

Forecast return on equity

Is REVB forecast to generate an efficient return?

Company
120.01%
Industry
75.1%
Market
170.33%
REVB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is REVB forecast to generate an efficient return on assets?

Company
103.61%
Industry
28.98%
REVB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

REVB earnings per share forecast

What is REVB's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$4.24
Avg 2 year Forecast
-$3.36
Avg 3 year Forecast
$1.85

REVB revenue forecast

What is REVB's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$25.9M

REVB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REVB$1.04N/AN/A
GOVX$1.37$1.00-27.01%Hold
SXTP$1.50$14.10+840.00%Buy
ALZN$1.02$28.00+2,645.10%Buy
INDP$1.73N/AN/A
View Top Biotech Stocks

Revelation Biosciences Stock Forecast FAQ

What is REVB's earnings growth forecast for 2026-2028?

(NASDAQ: REVB) Revelation Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.27%.

Revelation Biosciences's earnings in 2026 is -$21,504,759.On average, 4 Wall Street analysts forecast REVB's earnings for 2026 to be -$16,564,275, with the lowest REVB earnings forecast at -$21,794,132, and the highest REVB earnings forecast at -$10,752,063. On average, 4 Wall Street analysts forecast REVB's earnings for 2027 to be -$13,135,809, with the lowest REVB earnings forecast at -$16,240,267, and the highest REVB earnings forecast at -$9,644,026.

In 2028, REVB is forecast to generate $7,215,725 in earnings, with the lowest earnings forecast at $6,932,755 and the highest earnings forecast at $7,427,952.

If you're new to stock investing, here's how to buy Revelation Biosciences stock.

What is REVB's revenue growth forecast for 2026-2028?

(NASDAQ: REVB) Revelation Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.

Revelation Biosciences's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast REVB's revenue for 2026 to be $0, with the lowest REVB revenue forecast at $0, and the highest REVB revenue forecast at $0. On average, 4 Wall Street analysts forecast REVB's revenue for 2027 to be $0, with the lowest REVB revenue forecast at $0, and the highest REVB revenue forecast at $0.

In 2028, REVB is forecast to generate $101,192,902 in revenue, with the lowest revenue forecast at $97,221,948 and the highest revenue forecast at $104,167,210.

What is REVB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: REVB) forecast ROA is 103.61%, which is higher than the forecast US Biotechnology industry average of 28.98%.

What is REVB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: REVB) Revelation Biosciences's current Earnings Per Share (EPS) is -$22.76. On average, analysts forecast that REVB's EPS will be -$4.24 for 2026, with the lowest EPS forecast at -$5.58, and the highest EPS forecast at -$2.75. On average, analysts forecast that REVB's EPS will be -$3.36 for 2027, with the lowest EPS forecast at -$4.16, and the highest EPS forecast at -$2.47. In 2028, REVB's EPS is forecast to hit $1.85 (min: $1.77, max: $1.90).

What is REVB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: REVB) forecast ROE is 120.01%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.